Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 millionInvivyd in vitro data showed continued ...
Cumulative culture -- the accumulation of technological modifications and improvements over generations -- allowed humans to adapt to a diversity of environments and challenges. But, it is unclear ...
Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody adintrevimab from the EVADE study, demonstrating minimal tolerability issuesResults allow for ...
Dig down, and evolution by natural selection is just about spontaneous, sustained accumulation of complexity – if life elsewhere exists, it’s likely to develop in the same way ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results